Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

AIM: To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral s...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Obes Metab
Main Authors: Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina
Format: Artigo
Sprog:Inglês
Udgivet: Blackwell Publishing Ltd 2020
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7064975/
https://ncbi.nlm.nih.gov/pubmed/31903692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13955
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker